Does patient-tailored immunotherapy pave the way for new renal cell carcinoma treatment perspectives?

Van Brussel, Ilse; Van Craenenbroeck, Amaryllis H; Schrijvers, Dorien M; Cools, Nathalie.

Afiliação

Van Brussel I; 1 Laboratory of Pharmacology, University of Antwerp, B-2610 Antwerp, Belgium ; 2 Division of Nephrology-Hypertension, Antwerp University Hospital, B-2650 Edegem, Antwerp, Belgium ; 3 Laboratory of Physiopharmacology, University of Antwerp, B-2610 Antwerp, Belgium ; 4 Laboratory of Experimental Hemat
Van Craenenbroeck AH; 1 Laboratory of Pharmacology, University of Antwerp, B-2610 Antwerp, Belgium ; 2 Division of Nephrology-Hypertension, Antwerp University Hospital, B-2650 Edegem, Antwerp, Belgium ; 3 Laboratory of Physiopharmacology, University of Antwerp, B-2610 Antwerp, Belgium ; 4 Laboratory of Experimental Hemat
Schrijvers DM; 1 Laboratory of Pharmacology, University of Antwerp, B-2610 Antwerp, Belgium ; 2 Division of Nephrology-Hypertension, Antwerp University Hospital, B-2650 Edegem, Antwerp, Belgium ; 3 Laboratory of Physiopharmacology, University of Antwerp, B-2610 Antwerp, Belgium ; 4 Laboratory of Experimental Hemat
Cools N; 1 Laboratory of Pharmacology, University of Antwerp, B-2610 Antwerp, Belgium ; 2 Division of Nephrology-Hypertension, Antwerp University Hospital, B-2650 Edegem, Antwerp, Belgium ; 3 Laboratory of Physiopharmacology, University of Antwerp, B-2610 Antwerp, Belgium ; 4 Laboratory of Experimental Hemat

Transl Androl Urol ; 2(2): 85-8, 2013 Jun.

Article em En | MEDLINE | ID: mdl-26816729

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2013 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2013 Tipo de documento: Article